Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer
- 1 September 2018
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 69, 164-176
- https://doi.org/10.1016/j.ctrv.2018.06.019
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- Dermatologic Adverse Events to Targeted Therapies in Lower GI Cancers: Clinical Presentation and ManagementCurrent Treatment Options in Oncology, 2013
- Pazopanib versus Sunitinib in Metastatic Renal-Cell CarcinomaThe New England Journal of Medicine, 2013
- Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk FactorsJournal of Cancer Epidemiology, 2013
- Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysisJournal of Human Hypertension, 2013
- A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumoursBritish Journal of Cancer, 2012
- Unique Metabolic Pathway of [14C]Lenvatinib after Oral Administration to Male Cynomolgus MonkeyDrug Metabolism and Disposition, 2011
- Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and SunitinibOncology, 2009
- Guidelines for the management of chronic kidney diseaseCMAJ : Canadian Medical Association Journal, 2008
- Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinibAnnals of Oncology, 2008
- Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinibClinical and Experimental Medicine, 2007